What does this research mean for the field?

GLP-1 receptor agonists influence the risk of colorectal cancer in drug-naive patients with type 2 diabetes compared to non-GLP-1RA antidiabetic medications. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

December 7, 2023JAMA OncologyOpen Access

GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity

View Full Paper

Ask AI

Bookmark

Abstract

This cohort study compares glucagon-like peptide 1 receptor agonists (GLP-1RAs) with 7 non–GLP-1RA antidiabetics among drug-naive patients with type 2 diabetes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2023) studied this question.

synapsesocial.com/papers/6a062e73ac5820011f109e46 https://doi.org/10.1001/jamaoncol.2023.5573

View Full Paper

Ask AI

Bookmark

Abstract

This cohort study compares glucagon-like peptide 1 receptor agonists (GLP-1RAs) with 7 non–GLP-1RA antidiabetics among drug-naive patients with type 2 diabetes.

GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity

Abstract

Discussion

Cite This Study

GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity

Abstract

Discussion

Cite This Study

Keep reading

Keep reading